Subscribe to Newsletter
Subspecialties Oncology, Histology, Microscopy and imaging

Case of the Month

A 60-year-old male with a history of nonmelanoma skin cancer presents with a bothersome preauricular nodule.

Based on the morphologic findings, what is the diagnosis?

  1. Squamous cell carcinoma
  2. Warty dyskeratoma
  3. Acantholytic actinic keratosis
  4. Darier disease

Figure 1. Skin, preauricular nodule, 10x.

Figure 2. Skin, preauricular nodule, 20x.

Figure 3. Papillary structures, 40x.

Figure 4. Dyskeratosis, 40x.

Click here to register your guess.

Do you have an interesting case that you would like us to feature? Email it to [email protected].

Answer to March/April's Case of the Month

d. Low-grade oncocytic tumor

Low-grade oncocytic tumor (LOT) of the kidney is an emerging entity, recently recognized by the Genitourinary Pathology Society (GUPS) (1) and mentioned in the latest WHO Classification of Tumours in the chapter, “Other oncocytic tumors of the kidney (2).”

LOT usually affects older patients (median age 66 years) and is solitary and sporadic. Grossly, it is a small, circumscribed, tan to brown solid tumor with or without cystic areas (Figure 1). Its prognosis is generally good.

Histologically, LOT shows compact nests, solid sheets, or a trabecular growth and is composed of bland oncocytic cells with round low-grade nuclei, usually with perinuclear clearing but without membrane irregularity (Figure 2). Often, it has characteristic sharp areas of edema where cells become discohesive, stretched out, or interconnected in short strands (Figure 3).

Main differential diagnoses include oncocytomas, hybrid oncocytic tumors, and other renal cell carcinomas (RCC) such as the eosinophilic subtype of chromophobe RCC (ChRCC), eosinophilic solid cystic RCC (ESC-RCC), and succinate dehydrogenase-deficient RCC (SDH-RCC).

The nuclei characteristics are useful to distinguish LOTs from oncocytomas, which lack a perinuclear halo, and from ChRCC, which have additional nuclear membrane irregularities. The immunohistochemical profile of diffuse cytokeratin 7 positivity (Figure 4) with a negative to weak CD117 staining (only dispersed mast cells) (Figure 5), which is typical of LOT, is also useful. Colloidal iron staining has been reported as either negative, only apical/luminal, or bar-/block-like (3) (Figure 6).

Distinction from SDH-RCC, hybrid oncocytic tumor in the context of Birt-Hogg-Dubé syndrome, or ESC-RCC is generally possible on clinical and morphologic grounds alone, but further SDHB immunohistochemistry studies or detection of FLCN or TSC gene mutations could be warranted. These tumors are also associated with TSC and mTOR mutations.

Submitted by Tiago Oliveira, anatomical pathology resident, and Dolores López-Presa, anatomical pathologist at Hospital de Santa Maria, CHULN - Lisbon, Portugal.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. K Trpkov et al., “Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia,” Mod Pathol, 34, 1167 (2021). PMID: 33526874.
  2. H Moch et al., “Other oncocytic tumours of the kidney,” WHO Classification of Tumours, 5th edition, volume 8. IARC Publications: 2022.
  3. K Trpkov et al. “Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity?” Histopathology, 75, 174 (2019). PMID: 30895640.
Related Application Notes
Tumor Genomic Profiling with SureSelect Cancer Tumor-Specific Assays

| Contributed by Agilent

Comprehensive Genomic Profiling with SureSelect Cancer CGP Assay

| Contributed by Agilent

Preventing Bias in scRNAseq Performed on Solid Tumors

| Contributed by Revvity

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register